{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:46:43Z","timestamp":1759340803845},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.lpm.2006.11.031","type":"journal-article","created":{"date-parts":[[2008,1,26]],"date-time":"2008-01-26T00:54:08Z","timestamp":1201308848000},"page":"1418-1426","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Syndromes neurologiques paran\u00e9oplasiques"],"prefix":"10.1016","volume":"36","author":[{"given":"Jean-Christophe","family":"Antoine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2006.11.031_bib1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2006.11.031_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1474-4422(02)00135-7","article-title":"Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy","volume":"1","author":"Voltz","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lpm.2006.11.031_bib3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2006.11.031_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0035-3787(04)70890-5","article-title":"Les neuropathies p\u00e9riph\u00e9riques paran\u00e9oplasiques","volume":"160","author":"Antoine","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.lpm.2006.11.031_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1212\/WNL.57.4.719","article-title":"Response to cancer therapy in a patient with a paraneoplastic choreiform disorder","volume":"57","author":"Croteau","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2006.11.031_bib6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/jnnp.70.6.814","article-title":"Paraneoplastic opsoclonus-myoclonus associated with renal cell carcinoma and responsive to tumour ablation","volume":"70","author":"Vigliani","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2006.11.031_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000087447","article-title":"Amyotrophic lateral sclerosis mortality in 1.9million US cancer survivors","volume":"25","author":"Freedman","year":"2005","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.lpm.2006.11.031_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11926-002-0087-9","article-title":"Malignancy in patients with inflammatory myopathy","volume":"4","author":"Buchbinder","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.lpm.2006.11.031_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00415-004-0317-3","article-title":"Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study","volume":"251","author":"Vigliani","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.lpm.2006.11.031_bib10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2006.11.031_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1196\/annals.1254.019","article-title":"Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome","volume":"998","author":"Lang","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.lpm.2006.11.031_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/01.WNL.0000041495.87539.98","article-title":"Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease","volume":"60","author":"Bernal","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2006.11.031_bib13","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2006.11.031_bib14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2006.11.031_bib15","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-Ma2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2006.11.031_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.20269","article-title":"Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2006.11.031_bib17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp.2003.025171","article-title":"A follow up study of patients with paraneoplastic neurological disease in the United Kingdom","volume":"75","author":"Candler","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2006.11.031_bib18","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2006.11.031_bib19","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/brain\/124.11.2223","article-title":"The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders","volume":"124","author":"Rees","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2006.11.031_bib20","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/brain\/awh247","article-title":"FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes","volume":"127","author":"Younes-Mhenni","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.lpm.2006.11.031_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1634\/theoncologist.11-3-292","article-title":"Managing paraneoplastic neurological disorders","volume":"11","author":"de Beukelaar","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.lpm.2006.11.031_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","article-title":"Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies","volume":"60","author":"Uchuya","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2006.11.031_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","article-title":"Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone","volume":"68","author":"Keime-Guibert","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.lpm.2006.11.031_bib24","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.53.8.1719","article-title":"Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor","volume":"53","author":"Keime-Guibert","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2006.11.031_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/jnnp.62.3.276","article-title":"Spontaneous neurological improvement in anti-Hu associated encephalomyelitis","volume":"62","author":"Byrne","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207001947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207001947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T02:54:09Z","timestamp":1546311249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498207001947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0755498207001947"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2006.11.031","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}